Cargando…
The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
BACKGROUND: Patients with locally advanced rectal cancer (LARC) are at higher risk of local and distant recurrence and are thus more vulnerable to metastatic diseases. Neoadjuvant chemoradiotherapy (nCRT) and subsequent curative resection with total mesorectal excision (TME) followed by adjuvant che...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242658/ https://www.ncbi.nlm.nih.gov/pubmed/32499700 http://dx.doi.org/10.3389/fphar.2020.00706 |
_version_ | 1783537273843744768 |
---|---|
author | Zhong, Xi Zhou, Yue Cui, Wanbin Su, Xin Guo, Zhexu Hidasa, Iko Li, Qincai Wang, Zhenning Song, Yongxi |
author_facet | Zhong, Xi Zhou, Yue Cui, Wanbin Su, Xin Guo, Zhexu Hidasa, Iko Li, Qincai Wang, Zhenning Song, Yongxi |
author_sort | Zhong, Xi |
collection | PubMed |
description | BACKGROUND: Patients with locally advanced rectal cancer (LARC) are at higher risk of local and distant recurrence and are thus more vulnerable to metastatic diseases. Neoadjuvant chemoradiotherapy (nCRT) and subsequent curative resection with total mesorectal excision (TME) followed by adjuvant chemotherapy have been recommended by the National Comprehensive Cancer Network (NCCN) guidelines as standard of care for LARC patients. However, the efficacy of the addition of epidermal growth factor receptor (EGFR) inhibitors in kirsten rat sarcoma viral oncogene (KRAS)-wild type LARC patients remains uncertain. MATERIALS: PubMed, Embase, and Web of Science were searched to retrieve records on the application of EGFR inhibitors in a neoadjuvant setting for LARC patients. pCR was used as surrogate endpoint to perform data synthesis in a single-arm setting. RESULTS: Ten cohorts covering 540 subjects were eligible in this systematic review. The pooled pCR rate for EGFR inhibitors was 15% (95% confidence interval (95% CI), 11–20%; I(2) = 55.2%); the pooled estimates of Grade 3/4 diarrhea, Grade 3/4 hand–foot syndrome, Grade 3/4 acneiform rash were 17% (95% CI, 4–34%; I(2) = 93.3%), 2% (95% CI, 0–5%; I(2) = 13.7%), and 15% (95% CI, 9–22%; I(2) = 65.4%), respectively. CONCLUSION: The addition of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients provides comparable efficacy and acceptable safety. However, the results should be interpreted cautiously due to the small amount of relevant data and need further confirmation by more future studies. |
format | Online Article Text |
id | pubmed-7242658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72426582020-06-03 The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis Zhong, Xi Zhou, Yue Cui, Wanbin Su, Xin Guo, Zhexu Hidasa, Iko Li, Qincai Wang, Zhenning Song, Yongxi Front Pharmacol Pharmacology BACKGROUND: Patients with locally advanced rectal cancer (LARC) are at higher risk of local and distant recurrence and are thus more vulnerable to metastatic diseases. Neoadjuvant chemoradiotherapy (nCRT) and subsequent curative resection with total mesorectal excision (TME) followed by adjuvant chemotherapy have been recommended by the National Comprehensive Cancer Network (NCCN) guidelines as standard of care for LARC patients. However, the efficacy of the addition of epidermal growth factor receptor (EGFR) inhibitors in kirsten rat sarcoma viral oncogene (KRAS)-wild type LARC patients remains uncertain. MATERIALS: PubMed, Embase, and Web of Science were searched to retrieve records on the application of EGFR inhibitors in a neoadjuvant setting for LARC patients. pCR was used as surrogate endpoint to perform data synthesis in a single-arm setting. RESULTS: Ten cohorts covering 540 subjects were eligible in this systematic review. The pooled pCR rate for EGFR inhibitors was 15% (95% confidence interval (95% CI), 11–20%; I(2) = 55.2%); the pooled estimates of Grade 3/4 diarrhea, Grade 3/4 hand–foot syndrome, Grade 3/4 acneiform rash were 17% (95% CI, 4–34%; I(2) = 93.3%), 2% (95% CI, 0–5%; I(2) = 13.7%), and 15% (95% CI, 9–22%; I(2) = 65.4%), respectively. CONCLUSION: The addition of EGFR inhibitors in the nCRT for KRAS-wild type LARC patients provides comparable efficacy and acceptable safety. However, the results should be interpreted cautiously due to the small amount of relevant data and need further confirmation by more future studies. Frontiers Media S.A. 2020-05-15 /pmc/articles/PMC7242658/ /pubmed/32499700 http://dx.doi.org/10.3389/fphar.2020.00706 Text en Copyright © 2020 Zhong, Zhou, Cui, Su, Guo, Hidasa, Li, Wang and Song http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhong, Xi Zhou, Yue Cui, Wanbin Su, Xin Guo, Zhexu Hidasa, Iko Li, Qincai Wang, Zhenning Song, Yongxi The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis |
title | The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis |
title_full | The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis |
title_fullStr | The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis |
title_full_unstemmed | The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis |
title_short | The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis |
title_sort | addition of egfr inhibitors in neoadjuvant therapy for kras-wild type locally advanced rectal cancer patients: a systematic review and meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242658/ https://www.ncbi.nlm.nih.gov/pubmed/32499700 http://dx.doi.org/10.3389/fphar.2020.00706 |
work_keys_str_mv | AT zhongxi theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT zhouyue theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT cuiwanbin theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT suxin theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT guozhexu theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT hidasaiko theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT liqincai theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT wangzhenning theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT songyongxi theadditionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT zhongxi additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT zhouyue additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT cuiwanbin additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT suxin additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT guozhexu additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT hidasaiko additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT liqincai additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT wangzhenning additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis AT songyongxi additionofegfrinhibitorsinneoadjuvanttherapyforkraswildtypelocallyadvancedrectalcancerpatientsasystematicreviewandmetaanalysis |